Level Four Advisory Services, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Level Four Advisory Services, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$692.45 - $844.37 $69,245 - $84,437	100 Added 21.01%	576 $474,000
Q2 2023 Jul 10, 2023	BUY	$700.03 - $830.35 $143,506 - $170,221	205 Added 75.65%	476 $342,000
Q1 2023 Jun 05, 2023	SELL	$680.49 - $826.97 $16,331 - $19,847	-24 Reduced 8.14%	271 $222,000
Q4 2022 Feb 13, 2023	BUY	$705.89 - $766.39 $2,117 - $2,299	3 Added 1.03%	295 $212,000
Q3 2022 Nov 07, 2022	SELL	$573.97 - $724.32 $37,308 - $47,080	-65 Reduced 18.21%	292 $201,000
Q2 2022 Aug 08, 2022	SELL	$548.35 - $738.84 $74,027 - $99,743	-135 Reduced 27.44%	357 $211,000
Q1 2022 May 10, 2022	BUY	$595.12 - $698.43 $71,414 - $83,811	120 Added 32.26%	492 $344,000
Q4 2021 Feb 11, 2022	BUY	$543.48 - $670.97 $202,174 - $249,600	372 New	372 $235,000
Q3 2021 Oct 12, 2021	SELL	$574.03 - $680.96 $2.11 Million - $2.5 Million	-3,670 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$472.8 - $558.54 $1.74 Million - $2.05 Million	3,670 New	3,670 $2.05 Million

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Level Four Advisory Services, LLC with notifications on news.